#USA #New York #Pomerantz LLP #Nektar Therapeutics #SEC violations

Pomerantz Law Firm Files Class Action Lawsuit Against Nektar Therapeutics

On April 2, 2026, Pomerantz LLP announced the initiation of a class action lawsuit targeting Nektar Therapeutics Inc. (NASDAQ: NKTR) and certain of its executive officers. This lawsuit, filed in the United States District Court for the Northern District of California, is officially designated under docket number 26-cv-01951. It is aimed at representing all individuals and entities, excluding the defendants, who purchased or otherwise acquired Nektar securities during a specified time frame from February 26, 2025, to December 15, 2025. The primary objective is to recover damages linked to purported violations of federal securities laws and to seek remedies based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, complemented by Rule 10b-5.

Anyone who bought Nektar securities within the defined Class Period is encouraged to act quickly, as they have until May 5, 2026, to petition the court to be appointed as the Lead Plaintiff in this class action. Interested investors can obtain a copy of the complaint from Pomerantz Law Firm's website. Queries about this litigation can be directed to Danielle Peyton at [email protected] or by calling 646-581-9980, toll-free at 888-4-POMLAW, Ext. 7980. For effective communication, those reaching out via email should provide their mailing address, telephone number, and the number of shares purchased.

Nektar's Business and Controversies

Nektar Therapeutics is a biopharmaceutical enterprise dedicated to the discovery and development of therapies aiming to selectively modulate the immune system for treating autoimmune disorders. The flagship product of Nektar is rezpegaldesleukin, referred to as REZPEG or NKTR-358, which is a pioneering regulatory T cell stimulator intended for conditions such as alopecia areata.

In March 2024, Nektar launched the Phase 2b REZOLVE-AA trial designed to examine the effectiveness of rezpegaldesleukin in 94 patients suffering from severe to very severe alopecia areata who had not previously received treatment with Janus kinase inhibitors or other biologics. The enrollment criteria outlined stringent requirements such as the necessity of an accurate diagnosis of severe to very severe alopecia areata, based on the Severity of Alopecia Tool score. Additionally, individuals with unstable conditions in the preceding six months, inadequate washout periods from past treatments, or those presenting diffuse alopecia were excluded from participating in the trial.

By February 2025, Nektar announced the successful completion of target enrollment in the REZOLVE-AA trial. Throughout this period, the defendants consistently asserted that participant enrollment adhered to relevant instructions and protocol standards while promoting the company's pharmaceutical development expertise as instrumental in the advancement of its product candidates through clinical phases.

The class action complaint asserts that during the entirety of the defined Class Period, the defendants issued materially false and misleading declarations about the company’s operations, business practices, and compliance procedures. The allegations indicate several critical points of misrepresentation:
1. The enrollment process for the REZOLVE-AA trial did not conform to the mandated instructions and protocols.
2. This deviation was likely to adversely affect the results of the REZOLVE-AA trial.
3. Consequently, the integrity and prospects of the REZOLVE-AA trial were exaggerated.
4. As a result, the public statements made by the defendants were materially false and misleading at all times.

Emergence of the Truth

The situation escalated on December 16, 2025, when Nektar released a press announcement during pre-market hours, revealing topline outcomes from the 36-week induction treatment phase of the REZOLVE-AA trial. This press release disclosed that the trial did not achieve statistical significance, a failure attributed to the inclusion of four ineligible participants. Following this revelation, Nektar's stock experienced a sharp decline of $4.14 per share, equating to a 7.77% drop, closing at $49.16 per share on that very same day.

About Pomerantz LLP

Pomerantz LLP is widely regarded as a leading law firm specializing in corporate, securities, and antitrust class actions, with a presence in several major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. The firm, founded by Abraham L. Pomerantz, often referred to as the dean of the class action bar, has pioneered the field of securities class action and for over 85 years has fought tirelessly for the rights of victims of securities fraud and corporate misconduct, recovering billions of dollars for class members. For additional information, visit pomlaw.com.

This is attorney advertising, and past results do not guarantee similar outcomes.